Article ; Online: Effects of Tocilizumab on Adults With COVID-19 Pneumonia
Frontiers in Medicine, Vol
A Meta-Analysis
2022 Volume 9
Abstract: BackgroundCoronavirus disease-2019 (COVID-19), a worldwide disaster, has already affected lots of people. Effective care and therapy are currently being evaluated in full swing.PurposeOur purpose was to investigate the effects of tocilizumab, an ... ...
| Abstract | BackgroundCoronavirus disease-2019 (COVID-19), a worldwide disaster, has already affected lots of people. Effective care and therapy are currently being evaluated in full swing.PurposeOur purpose was to investigate the effects of tocilizumab, an interleukin-6 receptor inhibitor, on treatment of adult patients with COVID-19 pneumonia.Data Sources, Study Selection, and Data ExtractionWe conducted a meta-analysis and searched for relevant studies on Pubmed, Embase, and the Cochrane Library without restrictions on language from inception until February 1, 2021. Fifteen studies were included for this meta-analysis. Two authors independently selected and screened these studies, assessed the quality of included studies, and extracted related information.ResultsFifteen studies were included in this meta-analysis. The main studies showed that tocilizumab was associated with lower mortality (risk ratio = 0.62, 95% confidence interval = 0.46–0.83; and hazard ratio = 0.61, 95% confidence interval = 0.51–0.72). Using tocilizumab might also affect biochemistry indicators (lowered C-reactive protein and ferritin, increased lymphocyte count).ConclusionThese current bodies of evidence could indicate that early use of tocilizumab was associated with lower mortality in adult patients with COVID-19. Early use of tocilizumab could reduce the mortality rate of adult patients with COVID-19 without obvious fatal side effects, which may be a treatment option in patients with COVID-19 pneumonia.Systematic Review RegistrationThe study protocol was registered on PROSPERO (ID:242811). |
|---|---|
| Keywords | COVID-19 ; tocilizumab ; meta-analysis ; mortality ; side effects ; treatment ; Medicine (General) ; R5-920 |
| Subject code | 310 |
| Language | English |
| Publishing date | 2022-03-01T00:00:00Z |
| Publisher | Frontiers Media S.A. |
| Document type | Article ; Online |
| Database | BASE - Bielefeld Academic Search Engine (life sciences selection) |
Full text online
More links
Kategorien
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.